Bayesian Capital Management’s Ultragenyx Pharmaceutical RARE Stock Holding History

Bayesian Capital Management’s Portfolio RARE Stock Details RARE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q4	–	Sell	-13,100	Closed	-$394K	–	445
2025 Q3	$394K	Buy	+13,100	New	+$393K	0.08%	333
2025 Q2	–	Sell	-13,783	Closed	-$499K	–	813
2025 Q1	$499K	Buy	13,783 +5,515	+67%	+$229K	0.08%	294
2024 Q4	$348K	Sell	8,268 -5,568	-40%	-$276K	0.04%	457
2024 Q3	$769K	Buy	+13,836	New	+$705K	0.09%	284
2024 Q2	–	Sell	-15,302	Closed	-$714K	–	1029
2024 Q1	$714K	Buy	+15,302	New	+$722K	0.07%	368
2023 Q2	–	Sell	-16,263	Closed	-$652K	–	1010
2023 Q1	$652K	Buy	+16,263	New	+$698K	0.08%	324
2022 Q2	–	Sell	-9,200	Closed	-$668K	–	1030
2022 Q1	$668K	Buy	+9,200	New	+$640K	0.1%	297
2019 Q2	–	Sell	-3,753	Closed	-$260K	–	657
2019 Q1	$260K	Buy	+3,753	New	+$214K	0.05%	420

Other funds holding RARE

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Sands Capital Management Arlington, Virginia $26.9B AUM 34.44% 1-Year Est. Return

RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return

Bayesian Capital Management's RARE Position: Q4 2025 in Review

Bayesian Capital Management sold out of Ultragenyx Pharmaceutical (RARE) in Q4 2025, closing a stake of 13,100 shares — an estimated $394K sold.

Bayesian Capital Management first reported a position in RARE in Q1 2019 and held it in 8 quarters. The position peaked at $769K in Q3 2024. 288 funds tracked by Wall St. Rank hold RARE as of Q4 2025.

Bayesian Capital Management reported no remaining Ultragenyx Pharmaceutical position as of Q4 2025 after selling out during the quarter.
Bayesian Capital Management sold 13,100 Ultragenyx Pharmaceutical shares in Q4 2025, an estimated $394K.
Bayesian Capital Management first reported a position in Ultragenyx Pharmaceutical in Q1 2019 and held it in 8 quarters.
Bayesian Capital Management's Ultragenyx Pharmaceutical position peaked at $769K in Q3 2024.
288 funds tracked by Wall St. Rank held Ultragenyx Pharmaceutical as of Q4 2025.

Based on Bayesian Capital Management's 13F filing for Q4 2025, filed 17 Feb 2026.